MAG and COVID-19: A pilot study showed that GMA removed granulocyte subsets expressed CD11b, CD16, and CD66b, and weakly expressed CD11c, consistent with mature and activated neutrophils, and monocyte subsets strongly expressed CD14, suggesting that GMA can modulate the hypercytokinemia in COVID-19 [51].